European Commission approves ponesimod (Ponvory) for relapsing forms of multiple sclerosis (RMS) with active disease

Approval follows recent FDA approval in March 2021 and is based on data from the Phase III Optimum study where ponesimod demonstrated superior efficacy with an annualised relapse rate (ARR) reduction of 30.5% vs teriflunomide (Aubagio).

Source:

PharmaTimes